Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells

Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have therefore been developed. Despite this progress, not all...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Vanderhoeven, Fiorella, Redondo, Analía Lourdes, Martinez, Ana Laura, Vargas-Roig, Laura María, Sanchez, Angel Matias, Flamini, Marina Inés
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995169/
https://ncbi.nlm.nih.gov/pubmed/29899874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25480
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki